A panelist explains how the distinct mechanisms of erythropoiesis-stimulating agents (ESAs), luspatercept, and imetelstat ...

Bristol Myers Squibb has announced positive topline results from its phase 3 trial of Reblozyl (luspatercept-aamt), the first erythroid maturation agent for first-line treatment of patients with ...

In late 2019, the FDA approved luspatercept -- an erythroid maturation agent administered subcutaneously every 3 weeks -- for the treatment of anemia in adults with thalassemia who require regular ...

Myelodysplastic Syndrome Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035 The report provides a detailed analysis of the current myelodysplastic ...

If approved, it would compete with Bristol-Myers Squibb’s erythroid maturation agent Reblozyl (luspatercept), which was cleared to treat anaemia in adults with low-risk, relapsed MDS in 2020 and ...

These findings highlight the dual roles of antioxidants in cancer. Their impact depends on cancer type, stage, and genetic ...

Education for Sustainable Development empowers people with the knowledge, skills, values, attitudes and behaviors to live in a way that is good for the environment, economy, and society.

Drug development describes the process of developing a new drug that effectively targets a specific weakness in a cell. This process involves specific pre-clinical development and testing ...

Indian Renew Share Price: Find the latest news on Indian Renew Stock Price. Get all the information on Indian Renew with historic price charts for NSE / BSE. Experts & Broker view also get the ...

Activators of nuclear factor-erythroid 2-related factor 2 (NRF2) could lead to promising therapeutics for prevention and treatment of oxidative stress and inflammatory disorders. Ubiquitination and ...